{
    "Clinical Trial ID": "NCT00089661",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Denosumab 60 mg Q6M",
        "[Not Specified]",
        "INTERVENTION 2: ",
        "  Placebo",
        "[Not Specified]"
    ],
    "Eligibility": [
        "Histologically or cytologically confirmed adenocarcinoma of the breast",
        "  Subjects with early stage disease who are estrogen receptor positive and who have completed their treatment pathway (surgery, chemo-therapy, radiation, and/or hormone therapy) and are currently on or will initiate aromatase inhibitor therapy, and are expected to stay on aromatase inhibitor therapy for the duration of the 24-month study",
        "  All treatment pathway must be completed  4 weeks prior to study entry, and all acute toxic effect of any above therapy must be resolved to  Grade 1 by National Cancer Institution (NCI) Common Terminology Criteria for Adverse Events (CTCAE)",
        "  Female > 18 years of age",
        "  ECOG Performance status 0 and 1",
        "  Lumbar spine, total hip or femoral neck BMD equivalent to a t-score classification of -1.0 to -2.5",
        "  Subject is willing and able to provide signed consent before any study-specific procedure",
        "  Other criteria also apply."
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12",
        "  Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.",
        "  Time frame: 12 months",
        "Results 1: ",
        "  Arm/Group Title: Denosumab 60 mg Q6M",
        "  Arm/Group Description: [Not Specified]",
        "  Overall Number of Participants Analyzed: 123",
        "  Least Squares Mean (95% Confidence Interval)",
        "  Unit of Measure: Percent Change from Baseline  4.8        (4.3 to 5.4)",
        "Results 2: ",
        "  Arm/Group Title: Placebo",
        "  Arm/Group Description: [Not Specified]",
        "  Overall Number of Participants Analyzed: 122",
        "  Least Squares Mean (95% Confidence Interval)",
        "  Unit of Measure: Percent Change from Baseline  -.7        (-1.3 to -.1)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 11/120 (9.17%)",
        "  Acute myocardial infarction 0/120 (0.00%)",
        "  Atrial fibrillation 1/120 (0.83%)",
        "  Atrioventricular block second degree 0/120 (0.00%)",
        "  Cardiac failure congestive 1/120 (0.83%)",
        "  Myocardial infarction 0/120 (0.00%)",
        "  Myocardial ischaemia 1/120 (0.83%)",
        "  Goitre 1/120 (0.83%)",
        "  Colitis ischaemic 0/120 (0.00%)",
        "  Diverticulum 0/120 (0.00%)",
        "  Faecaloma 1/120 (0.83%)",
        "Adverse Events 2:",
        "  Total: 19/129 (14.73%)",
        "  Acute myocardial infarction 1/129 (0.78%)",
        "  Atrial fibrillation 0/129 (0.00%)",
        "  Atrioventricular block second degree 1/129 (0.78%)",
        "  Cardiac failure congestive 0/129 (0.00%)",
        "  Myocardial infarction 1/129 (0.78%)",
        "  Myocardial ischaemia 0/129 (0.00%)",
        "  Goitre 0/129 (0.00%)",
        "  Colitis ischaemic 1/129 (0.78%)",
        "  Diverticulum 1/129 (0.78%)",
        "  Faecaloma 0/129 (0.00%)"
    ]
}